Author Interviews, Depression, Hip Fractures, Lancet / 06.12.2018 Interview with: [caption id="attachment_46429" align="alignleft" width="100"]Prof .Gillian Mead Chair of Stroke and Elderly Care Medicine Prof. Mead[/caption] Prof. Gillian Mead Chair of Stroke and Elderly Care Medicine [caption id="attachment_46430" align="alignleft" width="100"]Prof Martin Dennis Chair of Stroke Medicine Prof. Dennis[/caption] Prof. Martin Dennis Chair of Stroke Medicine Centre for Clinical Brain Sciences The University of Edinburgh What is the background for this study? Response: We are both practicing stroke physicians as well as clinical trialists. Therefore our interest in this area was triggered by the exciting results of the FLAME trial in 2011. This appeared to indicate that fluoxetine might boost the recovery of stroke patients. Potentially this was very important given the increasing numbers of people having disability due to stroke, and the fact that fluoxetine is inexpensive and could be introduced very easily into clinical practice. We were further encouraged by the large numbers of small RCTs we identified when we carried out a Cochrane systematic review on the topic. These trials provided more evidence of potential benefit but there was evidence that trials of greater quality showed less benefit, and benefits were greater in patients who were depressed. We felt there was a need for more evidence derived from much larger numbers of patients.